For Immediate Release
U.S. STEM CELL CLINIC LAUNCHES BLOG TO EDUCATE CONSUMERS ON THE POWER OF STEM CELL THERAPY
Sunrise, FL – September 20, 2017 – U.S. Stem Cell Clinic (USCC), a privately-held Florida LLC and leader in novel regenerative medicine solutions and physician-based stem cell therapies for patients, today announced the launch of a new weekly blog to educate consumers on the power of using their body’s own healing potential through stem cell therapy. The blog is available at: https://usstemcellclinic.com/blog
“We are in the business of helping patients and simultaneously building brand and shareholder value,” said Michelle Parlo, Director of Clinical Operations at U.S. Stem Cell Clinic. “The new blog launch is another step in our efforts to arm consumers with up-to-date information backed by scientific research and most recent data on the state of the stem cell industry, provide answers to some of the most pressing questions, address misconceptions, and educate consumers on the ways stem cell therapy can help improve their lives. The consumer education blog complements the CEO Blog that has been published on a monthly basis by U.S. Stem Cell, Inc. and targeting the investment community.”
The first blog post that went out today highlights the ability of adult stem cells to reverse the effects of degenerative diseases like Osteoarthritis (OA) – the most common chronic condition of the joints, distressing approximately 27 million Americans. While typical OA treatments merely provide symptomatic relief from pain and surgical methods have limited long-term effects, a simple and safe outpatient stem cell procedure can help relieve the pain and improve quality of life for a patient, according to the article. The blog post explains how stem cell procedures are performed and features a video of an actual patient sharing results of the treatment he received at U.S. Stem Cell Clinic.
Based in Sunrise, FL, U.S. Stem Cell Clinic is an operating division of U.S. Stem Cell, Inc. and leader in novel regenerative medicine solutions and physician-based stem cell therapies for patients. The treatments performed at the Clinic help patient’s body restore itself by harnessing its own healing potential and combat areas of disease, injury or inflammation. This process involves a variety of techniques, including a minimally invasive outpatient procedure. During the procedure, cells and platelets may be isolated and delivered back to the same patient – all within three hours and with the full assistance of medically qualified staff pre, during, and post treatment. For more information about U.S. Stem Cell Clinic or to schedule a free consultation, visit: https://usstemcellclinic.com/
About U.S. Stem Cell, Inc.
US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.